IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of…
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of…
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of…
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the…
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of…
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of…
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in…
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in…
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders…
The award recognizes the OPTIREACH formulation technology developed in Oculis’ laboratory in Iceland by co-founders…
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response…
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response…
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime…
This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime…
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care…
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care…